Osteoblasts are single nucleus cells that synthesize bone, which function in groups of connected cells during the process of bone formation, as individual cells cannot create bone. Successful bone fusion relies on three crucial components: an osteoconductive matrix, an osteoinductive signal, and osteogenic cells.

Today, autograft bone is one of the most commonly used processes for bone grafting, and is often considered the traditional gold standard, containing all three components mentioned above. The Trinity ELITE and the Trinity Evolution allografts are both human donor bone grafts that contain a viable cancellous and a demineralized bone component, which also includes adult human mesenchymal cells and osteoprogenitor cells (MSCs and OPCs). These are retained within the cancellous bone matrix.

In a study conducted by a group of a members from New York University, SRM University in India, Orthofix, Inc., and the Department of Neurosurgery from the Mayo Clinic in Phoenix, Arizona, marker proteins and gene expressions were tested in bone chips. This was done to test their osteogenic and therapeutic abilities. Four different donor batches were tested, which were thawed and homogenized, then centrifuged using an RNA solution. For comparison, cultures of bone marrow cells (BMCs) derived from both human marrow and other Trinity Evolution samples were used.

The RNA isolation techniques implemented yielded great amounts of RNA for the analysis. The subsequent findings showed that the RNAs associated with MSCs and other bone-forming cells flourished at high to intermediate levels in both the Trinity ELITE and Trinity Evolution samples. For almost all of the genes tested, their levels of expression were either similar to or greater than cultures of BMCs.

In conclusion, both the Trinity ELITE and Trinity Evolution proved to have cell populations that exhibit high levels of gene expression with markers associated with MSCs, osteoprogenitors, and other bone-forming cells. Very low levels or no gene expression at all were shown with immunoreactive cells. This indicates that these cells did not flourish within the tissue, suggesting that this allogenic graft is much less likely to trigger an immune response.

These findings suggest that Trinity allografts possess material that contains an active osteogenic component that has the potential of contributing to bone healing in a clinical setting. Yet another finding that proves the efficiency and quality of Trinity products, and their high standards in the world of allografts and cell research.

For more on Orthofix products and allograft information in general, visit BennWillcox.net.